UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster

In US, 7% of psoriasis patients are starting or switching drugs every month

 
• By Kevin Grogan
  
Two leading hard currencies - US Dollar versus Euro
Bimekizumab expected to be a big earner on both sides of the Atlantic • Source: Archive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip